Takara Bio Inc. (JP:4974) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Takara Bio Inc. showcased mixed financial performance in its 22nd term, with net sales dropping to 43,505 million yen from the previous year’s 78,142 million yen, and a significant decline in profit attributable to owners of the parent to 1,480 million yen, compared to 16,012 million yen in the 21st term. Despite these downturns, the company has maintained a robust shareholders’ equity ratio of 92% and continued to invest heavily in research and development, especially in its Reagents and Instruments business and CDMO services for regenerative medicine and gene/cell therapy, accounting for 19.1% of net sales.
For further insights into JP:4974 stock, check out TipRanks’ Stock Analysis page.